Sanofi Can Move Forward to Pursue Deals -- Market Talk
Dow Jones2026/10/06 07:100710 GMT - Sanofi needs mergers and acquisitions to refill its late-stage drug pipeline, and its recently expanded collaboration with Regeneron Pharmaceuticals means it can shift its focus to dealmaking, Berenberg analysts say in a research note. "Sanofi can now move forward to deploy its [30 billion to 40 billion euros] of balance sheet capacity on business development," the analysts say. Since the drug candidates Sanofi and Regeneron will jointly develop are at an early stage, the French drugmaker has limited pivotal study results on the horizon, Berenberg says. Data on a late-stage trial for frexalimab in multiple sclerosis and a midstage for brivekimig in skin condition hidradenitis suppurativa due in the second half of 2027 are the next updates Berenberg will be watching, the analysts say. Sanofi shares rise 1%. (adria.calatayud@wsj.com) (END) Dow Jones Newswires October 06, 2026 03:10 ET (07:10 GMT)
0710 GMT - Sanofi needs mergers and acquisitions to refill its late-stage drug pipeline, and its recently expanded collaboration with Regeneron Pharmaceuticals means it can shift its focus to dealmaking, Berenberg analysts say in a research note. "Sanofi can now move forward to deploy its [30 billion to 40 billion euros] of balance sheet capacity on business development," the analysts say. Since the drug candidates Sanofi and Regeneron will jointly develop are at an early stage, the French drugmaker has limited pivotal study results on the horizon, Berenberg says. Data on a late-stage trial for frexalimab in multiple sclerosis and a midstage for brivekimig in skin condition hidradenitis suppurativa due in the second half of 2027 are the next updates Berenberg will be watching, the analysts say. Sanofi shares rise 1%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
October 06, 2026 03:10 ET (07:10 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
